Assessment of Drug Induced QT Interval Prolongation at a tertiary care, Baptist Hospital, Bangalore

被引:0
|
作者
Chaudhary, Zahra [1 ]
Ramaiah, Balakeshwa [1 ]
机构
[1] Karnataka Coll Pharm, Dept Pharm Practice, Pharm, Bengaluru, India
来源
关键词
QT-interval prolongation; ECG data; prescription pattern;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To investigate the drug induced QT-interval prolongation in hospital inpatients, predictors of risk factor for QT-interval prolongation and drug-drug interactions. Methodology: It is a prospective observational study conducted in inpatient setting. The data collected in pre design data collection form for 110 patients, who are assessed for the period of six months. The prescription with at least one QT-interval prolonging drugs were considered for this study. The collected data included demographics, mean change in QT-interval with drugs, ECG data and safety analysis data. Result: The total number of patients screened was 110. Among the study patients most of them 50.91% were older age. Major co-morbidities were diabetes mellitus 39(35.45%) and hypertension 36(32.72%). There was a high prevalence (46.45%) of QT-interval prolongation. The mean QTc in prolonged group was 495 +/- 34.4ms. Ondansetron (61.18%), Metronidazole (58.18%), Ciprofloxacin (20.9%), Azithromycin (16.36%) and Domperidone (11.81%) were associated with marked QTc-interval prolongation. Female sex, longer hospitalization, electrolyte abnormalities and older age were associated with drug induced QT-interval prolongation. 97(88.18%) prescriptions showed drug interaction involving QT-interval prolongation. The most common drug interaction was found to be between ondansetron and metronidazole in 41 prescription followed by ondansetron and ciprofloxacin in 15 prescriptions. Of the 97 interventions proposed, the most frequent suggestion was on stop/avoid/dose adjustment (13.40%) followed by ECG monitoring (10.40%). 16.49% of interventions were accepted Conclusion: This study demonstrates the high prevalence of a prolonged QT-interval in patients. Cardiac drugs and antibiotics were frequently involved in drug induced QT-interval prolongation. A simple ECG and a calculated QT interval can be used to plan management and caution consultant on probable electrolyte abnormalities and drug therapies. The current study demonstrated the importance of routine medication review and the need of a pharmacist in a multidisciplinary team.
引用
收藏
页码:1871 / 1874
页数:4
相关论文
共 50 条
  • [41] Drug-Induced QT/QTc Interval Shortening: Lessons from Drug-Induced QT/QTc Prolongation
    Marek Malik
    Drug Safety, 2016, 39 : 647 - 659
  • [42] Incidence and predictors of QT interval prolongation in the intensive care units of a tertiary pulmonary center
    Hosseinpoor, Zeinab
    Farzanegan, Behrooz
    Seyyedi, Seyyed Reza
    Rajabi, Mehdi
    Emami, Habib
    Baniasadi, Shadi
    EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [43] Drug Safety of Macrolide and Quinolone Antibiotics in a Tertiary Care Hospital: Administration of Interacting Comedication and QT-Prolongation
    Niedrig, David F.
    Machler, Sarah
    Hoppe, Liesa
    Corti, Natascia
    Kovari, Helen
    Russmann, Stefan
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 303 - 304
  • [44] Evaluation of drug-induced QT interval prolongation - Implications for drug approval and labelling
    Malik, M
    Camm, AJ
    DRUG SAFETY, 2001, 24 (05) : 323 - 351
  • [45] Prolongation of the QT interval in palliative care patients
    Walker, G
    Wilcock, A
    Carey, AM
    Manderson, C
    Weller, R
    Crosby, V
    JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2003, 26 (03) : 855 - 859
  • [46] A polygenic risk score for the QT interval is an independent predictor of drug-induced QT prolongation
    Simon, Steven T.
    Lin, Meng
    Trinkley, Katy E.
    Aleong, Ryan
    Rafaels, Nicholas
    Crooks, Kristy R.
    Reiter, Michael J.
    Gignoux, Christopher R.
    Rosenberg, Michael A.
    PLOS ONE, 2024, 19 (06):
  • [47] Evaluation of the QT interval in patients with drug-induced QT prolongation and torsades de pointes
    Krisai, Philipp
    Vlachos, Konstantinos
    Ramirez, F. Daniel
    Nakatani, Yosuke
    Nakashima, Takashi
    Takagi, Takamitsu
    Kamakura, Tsukasa
    Surget, Elodie
    Andre, Clementine
    Cheniti, Ghassen
    Welte, Nicolas
    Chauvel, Remi
    Tixier, Romain
    Duchateau, Josselin
    Pambrun, Thomas
    Derval, Nicolas
    Hocini, Meleze
    Jais, Pierre
    Hassaguerre, Michel
    Sacher, Frederic
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2020, 31 (10) : 2696 - 2701
  • [48] The preclinical assessment of the risk for QT interval prolongation
    Champeroux, P
    Martel, E
    Vannier, C
    Blanc, V
    Leguennec, JY
    Fowler, J
    Richard, S
    THERAPIE, 2000, 55 (01): : 101 - 109
  • [49] The assessment of potential for QT interval prolongation with new pharmaceuticals Impact on drug development
    Gralinski, MR
    JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 2000, 43 (02) : 91 - 99
  • [50] Assessment of drug-induced QT prolongation: To bin or not to bin?
    Malik, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 77 (04) : 241 - 246